ICCC
ICCC
NASDAQ · Biotechnology

Immucell Corp

$6.33
-0.10 (-1.56%)
As of Mar 31, 10:12 PM ET ·
Financial Highlights (FY 2026)
Revenue
26.98M
Net Income
-1,014,911
Gross Margin
41.4%
Profit Margin
-3.8%
Rev Growth
+14.2%
D/E Ratio
0.38
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 41.4% 41.4% 49.1% 49.1%
Operating Margin 6.0% 5.4% 4.8% 4.7%
Profit Margin -3.8% -3.6% 4.8% 5.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 26.98M 23.63M 25.83M 25.29M
Gross Profit 11.17M 9.78M 12.69M 12.42M
Operating Income 1.61M 1.27M 1.23M 1.19M
Net Income -1,014,911 -799,982 1.23M 1.32M
Gross Margin 41.4% 41.4% 49.1% 49.1%
Operating Margin 6.0% 5.4% 4.8% 4.7%
Profit Margin -3.8% -3.6% 4.8% 5.2%
Rev Growth +14.2% +14.2% +0.8% +23.4%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 7.95M 7.95M 3.09M 3.10M
Total Equity 20.77M 20.77M 31.72M 30.36M
D/E Ratio 0.38 0.38 0.10 0.10
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -1,004,339 -835,629 1.46M 1.67M
Free Cash Flow 1.13M 847.0K